Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with trastuzumab and vinorelbine in HER2-positive metastatic breast cancer
2006-001595-20Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in breast cancer and inflammatory breast cancer (IBC), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Relative dose intensity and 2 more. Started Feb 2007; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancerinflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2006-001595-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001595-20.